| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9974569 | The Journal of Heart and Lung Transplantation | 2005 | 5 Pages |
Abstract
OKT3 treatment in refractory pediatric heart transplant rejection is efficacious in acute rejection. OKT3 management in pediatric TxCAD is less clear, with no proven benefit identified in this study. OKT3 use in pediatric refractory heart rejection has significant side effects, but is tolerable and safe with close monitoring.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ivan MD, Kirk R. MD, Robert N. MD, Alexandria M. RN, William T. MD,